[go: up one dir, main page]

MX9703024A - Cristalizacion de levobupivacaina y sus analogos. - Google Patents

Cristalizacion de levobupivacaina y sus analogos.

Info

Publication number
MX9703024A
MX9703024A MX9703024A MX9703024A MX9703024A MX 9703024 A MX9703024 A MX 9703024A MX 9703024 A MX9703024 A MX 9703024A MX 9703024 A MX9703024 A MX 9703024A MX 9703024 A MX9703024 A MX 9703024A
Authority
MX
Mexico
Prior art keywords
levobupivacaine
crystallisation
analogues
resolving agent
analogue
Prior art date
Application number
MX9703024A
Other languages
English (en)
Inventor
Marianne Langston
Benjamin Mark Skead
Original Assignee
Chiroscience Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9421476A external-priority patent/GB9421476D0/en
Priority claimed from GBGB9504926.8A external-priority patent/GB9504926D0/en
Application filed by Chiroscience Ltd filed Critical Chiroscience Ltd
Publication of MX9703024A publication Critical patent/MX9703024A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Epoxy Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Non-Silver Salt Photosensitive Materials And Non-Silver Salt Photography (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La levobupivacaína o un análogo de la misma se prepara por la reaccion con el agente de resolucion ácido tartárico en un solvente, en presencia de agua y/o menos de 0.5 equivalente del agente de resolucion.
MX9703024A 1994-10-25 1995-10-23 Cristalizacion de levobupivacaina y sus analogos. MX9703024A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9421476A GB9421476D0 (en) 1994-10-25 1994-10-25 Process and salt
GBGB9504926.8A GB9504926D0 (en) 1995-03-10 1995-03-10 Crystallisation
PCT/GB1995/002513 WO1996012699A1 (en) 1994-10-25 1995-10-23 Crystallisation of levobupivacaine and analogues thereof

Publications (1)

Publication Number Publication Date
MX9703024A true MX9703024A (es) 1997-10-31

Family

ID=26305863

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9703024A MX9703024A (es) 1994-10-25 1995-10-23 Cristalizacion de levobupivacaina y sus analogos.

Country Status (16)

Country Link
US (1) US5994548A (es)
EP (1) EP0788480B1 (es)
JP (1) JP3911545B2 (es)
AT (1) ATE245629T1 (es)
AU (1) AU698637B2 (es)
CA (1) CA2200355C (es)
DE (1) DE69531356T2 (es)
DK (1) DK0788480T3 (es)
ES (1) ES2202375T3 (es)
FI (1) FI117438B (es)
HU (1) HU227420B1 (es)
MX (1) MX9703024A (es)
NO (1) NO309266B1 (es)
PL (1) PL183210B1 (es)
PT (1) PT788480E (es)
WO (1) WO1996012699A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0002246A (pt) * 2000-04-06 2003-04-15 Cristalia Prod Quimicos Farm Processo de obtenção dos enantiÈmeros da bupivacaìna racêmica, processo de obtenção de composições farmacêuticas a base de levobupivacaìna: composições farmacêuticas a base de levobupivacaìna formuladas nas formas básicas ou sais farmaceuticamente aceitáveis e utilização das composições farmacêuticas a base de levobupivacaìna formuladas nas formas básicas ou sais farmaceuticamente aceitáveis
BRPI0104491B8 (pt) * 2001-10-10 2021-05-25 Cristalia Produtos Quim Farmaceuticos Ltda n-(2,6-dimetilfenil)-1-propil-2-piperidinocarboxamida; processo de obtenção dos enantiômeros; mistura não racêmica dos anantiômeros e seu processo de obtenção e composição farmacêutica.
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
CN101797221B (zh) 2002-12-13 2013-06-12 杜雷科特公司 包含高粘度液体载体材料的口服递药系统
US7094812B2 (en) * 2003-04-24 2006-08-22 Xerox Corporations Colorant compositions
US6790267B1 (en) * 2003-04-24 2004-09-14 Xerox Corporation Colorant compositions
HUE032040T2 (en) 2004-09-17 2017-09-28 Durect Corp Saib-containing (sucrose acetate-isobutyrate) sustained-release local anesthetic composition
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
EP2010491A1 (en) * 2006-04-25 2009-01-07 Disham Pharmaceuticals and Chemicals Ltd. Ropivacaine hydrochloride anhydrate and the preparation thereof
US8337883B2 (en) 2006-11-03 2012-12-25 Durect Corporation Transdermal delivery systems
AU2008335809A1 (en) 2007-12-06 2009-06-18 Durect Corporation Methods useful for the treatment of pain, arthritic conditions, or inflammation associated with a chronic condition
PL2234974T3 (pl) * 2008-01-15 2012-09-28 Pharmathen Sa Sposób otrzymywania związku (s)-1-alkilo-2', 6'-pipekoloksylidydu
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
CN103073484B (zh) * 2013-01-28 2014-10-22 山东诚创医药技术开发有限公司 一种甲哌卡因及其光学对映体的制备方法
WO2014144975A1 (en) 2013-03-15 2014-09-18 Durect Corporation Compositions with a rheological modifier to reduce dissolution variability
CA3028450A1 (en) 2016-07-06 2018-01-11 Durect Corporation Oral dosage form with drug composition, barrier layer and drug layer
KR102422382B1 (ko) * 2016-12-26 2023-01-25 셀릭스 바이오 프라이빗 리미티드 통증 치료를 위한 조성물
WO2021146215A1 (en) 2020-01-13 2021-07-22 Durect Corporation Sustained release drug delivery systems with reduced impurities and related methods
JP2024503402A (ja) 2021-01-12 2024-01-25 デュレクト コーポレーション 徐放性薬物送達システム及び関連の方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE341404B (es) * 1967-05-18 1971-12-27 Sterling Drug Inc
US4695576A (en) * 1984-07-09 1987-09-22 Astra Lake Medel Aktiebolag L-N-n-propylpipecolic acid-2,6-xylidide

Also Published As

Publication number Publication date
NO309266B1 (no) 2001-01-08
HUT77631A (hu) 1998-06-29
DE69531356D1 (de) 2003-08-28
US5994548A (en) 1999-11-30
FI971711L (fi) 1997-04-22
AU698637B2 (en) 1998-11-05
EP0788480B1 (en) 2003-07-23
FI971711A0 (fi) 1997-04-22
DE69531356T2 (de) 2004-05-27
JP3911545B2 (ja) 2007-05-09
PT788480E (pt) 2003-12-31
EP0788480A1 (en) 1997-08-13
CA2200355A1 (en) 1996-05-02
NO971903L (no) 1997-04-24
NO971903D0 (no) 1997-04-24
HU227420B1 (en) 2011-05-30
WO1996012699A1 (en) 1996-05-02
JPH10507464A (ja) 1998-07-21
PL319829A1 (en) 1997-09-01
AU3704895A (en) 1996-05-15
ES2202375T3 (es) 2004-04-01
ATE245629T1 (de) 2003-08-15
CA2200355C (en) 2007-03-06
DK0788480T3 (da) 2003-09-29
PL183210B1 (pl) 2002-06-28
FI117438B (fi) 2006-10-13

Similar Documents

Publication Publication Date Title
MX9703024A (es) Cristalizacion de levobupivacaina y sus analogos.
DE69200983D1 (de) Verfahren zur Herstellung von Wasserstoffsuperoxyd.
DE69409148D1 (de) Verfahren zur Herstellung von Wasserstoffperoxid
EP0698031A4 (en) SIALYL LE x ANALOGUES AS INHIBITORS OF CELLULAR ADHESION
DE69101775D1 (de) Verfahren zur Herstellung von Wasserstoffperoxid.
DE60042375D1 (de) Verfahren zur Herstellung von 3,3-Dimethylbutanal
ATE57176T1 (de) Verfahren zur herstellung von (2,2)-paracyclophan und dessen abkoemmlinge.
ATE153022T1 (de) 3',5'-ditertbutyl-4'-hydroxyflavone, verfahren zu ihrer herstellung und pharmazeutische zusammensetzung mit antioxidations- und antivasokonstriktionsaktivität
DE69407653D1 (de) Verfahren zur Herstellung von Wasserstoffsuperoxyd
FI955130A0 (fi) L-aminohappo-oksidaasi
EP0260869A3 (en) Deodorant composition
DE69202680D1 (de) Verfahren zur Herstellung von Wasserstoffperoxyd.
DE59408701D1 (de) Verfahren zur Herstellung von 2,3,4,5-Tetrafluor-benzotrifluorid
AU5707090A (en) Hair treatment composition
DE59407675D1 (de) Verfahren zur Herstellung von 6H-Dibenz-(c,e)(1,2)-oxaphosphorin-6-on
DE69408085D1 (de) Verfahren zur Herstellung von 2,2-Diphenylhexafluorpropanen
EP0646625A3 (en) Fluorine-containing copolymer composition.
AU7771487A (en) Process for preventing corrosion and embodiments thereof
TW332199B (en) Process for the preparation of 3-chloropropionic acid
AU638829B2 (en) Composition for disinfecting water by the electrochlorination process and use of this composition
DE69427148D1 (de) Verfahren zur Herstellung von 2,4,5-Tribrompyrrol-3-carbonitril
DE3851325D1 (de) Gegen den Zellmembransynthese-Inhibitor resistente Mutante und Verfahren zu deren Herstellung.
AU2403592A (en) 2-aza-2-desamino analogues of 5,8-dideazafolic acid
DE69423702D1 (de) Verfahren zur Herstellung von 6,13-Dihydroquinacridonen
DE69226016D1 (de) Verfahren zur Herstellung von 2,4,5-Trihalobenzoesäure